View in EDS

Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis.

Saved in:
Bibliographic Details
Title: Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis.
Authors: Volpato M; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Perry SL; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Marston G; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Ingram N; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Cockbain AJ; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Burghel H; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Mann J; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Lowes D; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Wilson E; Leeds Institute of Cancer Studies and Pathology, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Droop A; Leeds Institute of Cancer Studies and Pathology, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom.; MRC Medical Bioinformatics Centre, University of Leeds, Leeds, LS2 9NL, UK., Randerson-Moor J; Leeds Institute of Cancer Studies and Pathology, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Coletta PL; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom., Hull MA; Leeds Institute of Biomedical & Clinical Sciences, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom.
Source: Oncotarget [Oncotarget] 2016 May 10; Vol. 7 (19), pp. 28139-50.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1949-2553
DOI:10.18632/oncotarget.8579